Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140806 | 1.00 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25901195 | 1.00 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25319179 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25901214 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25901221 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25316427 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25316946 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25318728 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25901215 | 0.93 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL25316356 | 0.92 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4469157-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, C1QBP, CFH | NPC1 322/4885RAB9A 1785/4885SMN1; SMN2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.